Price Alert

ADC Therapeutics S.A. (ADCT)

NYSE: ADCT · Real-Time Price · USD

3.46

-0.10 (-2.81%)

At close: Sep 25, 2025, 10:17 AM

ADC Therapeutics S.A. Statistics

Share Statistics

ADC Therapeutics S.A. has 112.5M shares outstanding. The number of shares has increased by 2.58% in one year.

Shares Outstanding	112.5M
Shares Change (YoY)	2.58%
Shares Change (QoQ)	0.1%
Owned by Institutions (%)	50.37%
Shares Floating	92.48M
Failed to Deliver (FTD) Shares	1,145
FTD / Avg. Volume	0.14%

Short Selling Information

The latest short interest is 4.14M, so 3.68% of the outstanding shares have been sold short.

Short Interest	4.14M
Short % of Shares Out	3.68%
Short % of Float	4.54%
Short Ratio (days to cover)	5.78

Valuation Ratios

The PE ratio is -1.22 and the forward PE ratio is -2.6. ADC Therapeutics S.A.'s PEG ratio is 0.03.

PE Ratio	-1.22
Forward PE	-2.6
PS Ratio	2.73
Forward PS	5
PB Ratio	-0.95
P/FCF Ratio	-1.55
PEG Ratio	0.03

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for ADC Therapeutics S.A..

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.82, with a Debt / Equity ratio of -0.61.

Current Ratio	3.82
Quick Ratio	3.59
Debt / Equity	-0.61
Debt / EBITDA	-1.19
Debt / FCF	-0.99
Interest Coverage	-2.6

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$269.34K
Profits Per Employee	$-600.17K
Employee Count	263
Asset Turnover	0.22
Inventory Turnover	0.32

Taxes

Income Tax	166K
Effective Tax Rate	-0.11%

Stock Price Statistics

The stock price has increased by 16.34% in the last 52 weeks. The beta is 2.01, so ADC Therapeutics S.A.'s price volatility has been higher than the market average.

Beta	2.01
52-Week Price Change	16.34%
50-Day Moving Average	3.13
200-Day Moving Average	2.3
Relative Strength Index (RSI)	61.14
Average Volume (20 Days)	845,477

Income Statement

In the last 12 months, ADC Therapeutics S.A. had revenue of 70.84M and earned -157.85M in profits. Earnings per share was -1.62.

Revenue	70.84M
Gross Profit	64.89M
Operating Income	-130.65M
Net Income	-157.85M
EBITDA	-103.71M
EBIT	-106.99M
Earnings Per Share (EPS)	-1.62

Full Income Statement

Balance Sheet

The company has 250.87M in cash and 123M in debt, giving a net cash position of 127.87M.

Cash & Cash Equivalents	250.87M
Total Debt	123M
Net Cash	127.87M
Retained Earnings	-1.49B
Total Assets	321.56M
Working Capital	254.16M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -123.83M and capital expenditures -867K, giving a free cash flow of -124.7M.

Operating Cash Flow	-123.83M
Capital Expenditures	-867K
Free Cash Flow	-124.7M
FCF Per Share	-1.28

Full Cash Flow Statement

Margins

Gross margin is 91.6%, with operating and profit margins of -184.44% and -222.83%.

Gross Margin	91.6%
Operating Margin	-184.44%
Pretax Margin	-220.42%
Profit Margin	-222.83%
EBITDA Margin	-146.41%
EBIT Margin	-184.44%
FCF Margin	-176.04%

Dividends & Yields

ADCT does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for ADCT is $8, which is 124.7% higher than the current price. The consensus rating is "Buy".

Price Target	$8
Price Target Difference	124.7%
Analyst Consensus	Buy
Analyst Count	5

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-6.56
Piotroski F-Score	3